6 results on '"Obara, Wataru"'
Search Results
2. Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study.
- Author
-
Sobu, Ryuta, Numakura, Kazuyuki, Naito, Sei, Hatakeyama, Shingo, Kato, Renpei, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Syuya, Kawamura, Sadafumi, Arai, Yoichi, Ito, Akihiro, Nishiyama, Hiroyuki, Kojima, Yoshiyuki, Obara, Wataru, Ohyama, Chikara, Tsuchiya, Norihiko, and Habuchi, Tomonori
- Subjects
RENAL cell carcinoma ,VASCULAR endothelial growth factor receptors ,CELL survival ,DISEASE risk factors - Abstract
It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the survival rates and predictive factors of early response in patients with metastatic renal cell carcinoma (mRCC) managed by VEGFR‐TKIs. From Jan. 2008 to Oct. 2018, 496 patients were treated with VEGFR‐TKIs as first‐line treatment at the eight Japanese hospitals (Michinoku RCC). Early cessation was defined as VEGFR‐TKIs being given up within 3 months after their initiation. The number of patients in early cessation VEGFR‐TKIs (Cohort I) was 173 (34.9%), and in long‐term use (Cohort II) was 323 (65.1%). The cancer‐specific survival (CSS) and overall survival (OS) were better in Cohort II. IMDC Poor‐risk was at risk of early cessation of a first‐line VEGFR‐TKI. Axitinib was the most preferred drug for long‐term treatment. On closer examination, both Cohort I and II were divided into two groups, the patients ceased VEGFR‐TKI due to adverse events (Group A [67 from Cohort I] and Group C [51 from Cohort II]) and disease progression (Group B [106 from Cohort I] and Group D [272 from Cohort II]). Despite that the cessation was adverse events, CSS and OS in Group A were worse than both Group C and D. Axitinib was administered with the safer profile. IMDC Poor risk was the risk factor for the early disease progression. Managing early adverse events may contribute to a better prognosis in mRCC patients treated VEGFR‐TKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era.
- Author
-
Numakura, Kazuyuki, Muto, Yumin, Naito, Sei, Hatakeyama, Shingo, Kato, Renpei, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Syuya, Kawamura, Sadafumi, Arai, Yoichi, Ito, Akihiro, Nishiyama, Hiroyuki, Kojima, Yoshiyuki, Obara, Wataru, Ohyama, Chikara, Tsuchiya, Norihiko, and Habuchi, Tomonori
- Subjects
RENAL cell carcinoma ,VASCULAR endothelial growth factors ,OVERALL survival ,SURVIVAL rate ,IMMUNE checkpoint inhibitors ,DISEASE relapse - Abstract
Although combination immune checkpoint inhibitor (immuno‐oncology [IO]) therapy is the first‐line treatment for metastatic renal cell carcinoma (mRCC), it mostly causes resistance and tumor regrowth. Therefore, an optimal second‐line therapy is necessary. Such therapy typically comprises vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR‐TKIs). This study was aimed at comparing the efficacy of two TKIs—axitinib and sunitinib—in mRCC patients. From January 2008 to October 2018, we registered 703 mRCC patients from 8 Japanese institutes. Of these, 408 patients received axitinib or sunitinib as the first‐line treatment. Thereafter, efficacy and survival rate were compared between the axitinib and sunitinib groups. To reduce the effects of selection bias and potential confounders, propensity score matching analysis was performed. Axitinib and sunitinib were administered in 274 and 134 patients, respectively. More than 25% of the patients received nivolumab sequence therapy. To calculate the propensity scores for each patient, we performed multivariate logistic regression analysis. The objective response rate, progression‐free survival (PFS), cause‐specific survival, and overall survival (OS) were significantly better in the axitinib group than in the sunitinib group. Furthermore, the OS was better in the nivolumab‐treated patients in the axitinib group. Axitinib showed higher efficacy and afforded greater survival benefits than did sunitinib when administered as first‐line therapy in mRCC patients. Thus, from among VEGFR‐TKIs, axitinib might be a possible option for application in the middle of IO drug‐based treatment sequences. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
- Author
-
Hatakeyama, Shingo, Naito, Sei, Numakura, Kazuyuki, Kato, Renpei, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Shuya, Kawamura, Sadafumi, Tsushima, Eiki, Nishiyama, Hiroyuki, Ito, Akihiro, Kojima, Yoshiyuki, Habuchi, Tomonori, Obara, Wataru, Tsuchiya, Norihiko, and Ohyama, Chikara
- Subjects
RENAL cell carcinoma ,PROTEIN-tyrosine kinases ,NEPHRECTOMY ,KINASE inhibitors ,AGE groups - Abstract
Objectives: To compare overall survival between patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy and those not treated by cytoreductive nephrectomy. Methods: We retrospectively evaluated 278 patients with metastatic renal cell carcinoma treated with first‐line tyrosine kinase inhibitors between January 2008 and November 2019. Patients were divided into two groups: a cytoreductive nephrectomy group (immediate or deferred cytoreductive nephrectomy) and a group who received systemic tyrosine kinase inhibitor therapies alone without cytoreductive nephrectomy (control group). Overall survival comparisons were made in all patients in the control versus the cytoreductive nephrectomy group, the control versus the immediate cytoreductive nephrectomy group, the control versus the deferred cytoreductive nephrectomy group, and the deferred cytoreductive nephrectomy versus the immediate cytoreductive nephrectomy group. Analyses were weighted using the propensity score‐based inverse probability of treatment weighting method to adjust for group imbalances. Results: The median (range) age of the patients was 65 (59–73) years. Of the 278 patients, 132 and 146 were in the control group and the cytoreductive nephrectomy (immediate, n = 107 and deferred, n = 39) group, respectively. A significant difference was noted between the control and cytoreductive nephrectomy groups in age, clinical stage, International Metastatic Renal Cell Carcinoma Database Consortium risk factors, and the number of metastatic sites. Inverse probability of treatment weighting‐adjusted Cox regression analysis showed a significant difference in overall survival between the control and the cytoreductive nephrectomy groups and between the control and the immediate or deferred cytoreductive nephrectomy groups. However, there was no significant difference in overall survival between the immediate and the deferred cytoreductive nephrectomy groups. Conclusions: Our findings suggest that metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy are more likely to have longer overall survival than those who receive tyrosine kinase inhibitor therapy only. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
- Author
-
Obara, Wataru, Mizutani, Yoichi, Oyama, Chikara, Akaza, Hideyuki, Ishii, Nobuhisa, Kohri, Kenjiro, Namiki, Mikio, Okuyama, Akihiko, Shima, Hiroki, Yokoyama, Masayoshi, Shuin, Taro, Miki, Tsuneharu, Watanabe, Yoshiyuki, and Fujioka, Tomoaki
- Subjects
- *
CANCER patients , *STEROID hormones , *RENAL cell carcinoma , *ANTINEOPLASTIC agents , *CANCER invasiveness - Abstract
Objectives: To assess the safety and efficacy of combined therapy with interferon-alpha (INF-α) and active vitamin D3 for metastatic renal cell carcinoma (RCC). Methods: Sixteen patients with metastatic RCC were enrolled in this prospective study. All received oral alfacalcidol (1 µg once daily) and INF-α (Sumiferon; 3 million units, three times a week). The primary endpoint was the response rate (defined as complete + partial remission). Secondary endpoints were cancer-specific survival and toxicity. The median follow-up period was 17 months (range: 5–49 months). Results: The median age of the patients was 68 years (range: 41–73 years). The sites of metastases were: lung in 13 patients, bone in one, lung and bone in one, and lung, bone, and lymph nodes in one. Four patients (25%) had a partial response (PR), 10 patients (62.5%) showed no change (NC), and two patients (12.5%) had progressive disease (PD). The median cancer-specific survival time was 45 months. One patient had to discontinue vitamin D3 because of hypercalcemia. Kaplan-Meier survival analysis revealed that metastasis at the time of initial diagnosis and older than average age were significant predictors of poor survival ( P < 0.05). Conclusions: Combined treatment with INF-α and active vitamin D3 has shown to be safe and effective for metastatic RCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
- Author
-
Okita, Kazutaka, Hatakeyama, Shingo, Naito, Sei, Numakura, Kazuyuki, Kato, Renpei, Koguchi, Tomoyuki, Kojima, Takahiro, Kawasaki, Yoshihide, Kandori, Shuya, Kawamura, Sadafumi, Nishiyama, Hiroyuki, Ito, Akihiro, Kojima, Yoshiyuki, Habuchi, Tomonori, Obara, Wataru, Tsuchiya, Norihiko, and Ohyama, Chikara
- Subjects
- *
RENAL cell carcinoma , *NEPHRECTOMY , *PROTEIN-tyrosine kinase inhibitors , *OVERALL survival , *MODEL validation , *DECISION making , *METASTASIS , *RETROSPECTIVE studies , *KIDNEY tumors , *CYTOREDUCTIVE surgery - Abstract
Objectives: This study aims to evaluate the utility of the scoring system of the Registry for Metastatic Renal Cell Carcinoma (REMARCC) model on the overall survival (OS) of patients undergoing cytoreductive nephrectomy (CN).Methods: A total of 278 patients with primary metastatic renal cell carcinoma (mRCC) treated with first-line tyrosine kinase inhibitors (TKIs) between January 2008 and November 2019 were identified. The c-index and net benefit between the REMARCC score were compared with the International mRCC Database Consortium (IMDC) score in patients with CN (CN group, n = 146). The effect of the REMARCC score on OS was compared between the CN group and patients without CN (non-CN group, n = 132) using Cox regression analysis under the propensity score-based inverse probability of treatment weighting (IPTW) method to adjust for group imbalances.Results: Of the 146 patients with CN, the c-index of the REMARCC model (0.60) was higher than the IMDC model (0.54). The decision curve analysis showed the advantage of REMARCC model predicting OS compared with the IMDC model. OS was significantly longer in the REMARCC low-score (0-2) than that in the high-score (3-6) among the patients with CN. IPTW-adjusted Cox regression analyses showed that OS was significantly longer in the CN group than that in the non-CN group among the patients with REMARCC low-score but was not significantly different between the groups among the patients with REMARCC high-score.Conclusions: The REMARCC score may be active for selecting the CN candidate in patients treated with TKIs. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.